334 related articles for article (PubMed ID: 25418144)
21. Experience using mTOR inhibitors for subependymal giant cell astrocytoma in tuberous sclerosis complex at a single facility.
Tomoto K; Fujimoto A; Inenaga C; Okanishi T; Imai S; Ogai M; Fukunaga A; Nakamura H; Sato K; Obana A; Masui T; Arai Y; Enoki H
BMC Neurol; 2021 Mar; 21(1):139. PubMed ID: 33784976
[TBL] [Abstract][Full Text] [Related]
22. Everolimus for subependymal giant cell astrocytoma: 5-year final analysis.
Franz DN; Agricola K; Mays M; Tudor C; Care MM; Holland-Bouley K; Berkowitz N; Miao S; Peyrard S; Krueger DA
Ann Neurol; 2015 Dec; 78(6):929-38. PubMed ID: 26381530
[TBL] [Abstract][Full Text] [Related]
23. Everolimus (RAD001): first systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
Józwiak S; Stein K; Kotulska K
Future Oncol; 2012 Dec; 8(12):1515-23. PubMed ID: 23231513
[TBL] [Abstract][Full Text] [Related]
24. The effect of mTOR inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
Weidman DR; Palasamudram S; Zak M; Whitney R; McCoy B; Bouffet E; Taylor M; Shroff M; Bartels U
J Neurooncol; 2020 May; 147(3):731-736. PubMed ID: 32285309
[TBL] [Abstract][Full Text] [Related]
25. Retinal astrocytoma regression in tuberous sclerosis patients treated with everolimus.
Zipori AB; Tehrani NN; Ali A
J AAPOS; 2018 Feb; 22(1):76-79. PubMed ID: 29277498
[TBL] [Abstract][Full Text] [Related]
26. Persistent communicating hydrocephalus in adult tuberous sclerosis patients: a possible therapeutic role for everolimus.
Laviv Y; Jackson S; Rappaport ZH
Acta Neurochir (Wien); 2015 Feb; 157(2):241-5. PubMed ID: 25524658
[TBL] [Abstract][Full Text] [Related]
27. Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study.
Franz DN; Belousova E; Sparagana S; Bebin EM; Frost MD; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Berkowitz N; Niolat J; Jóźwiak S
PLoS One; 2016; 11(6):e0158476. PubMed ID: 27351628
[TBL] [Abstract][Full Text] [Related]
28. Subependymal giant-cell astrocytoma: A surgical review in the modern era of mTOR inhibitors.
Danassegarane G; Tinois J; Sahler Y; Aouaissia S; Riffaud L
Neurochirurgie; 2022 Dec; 68(6):627-636. PubMed ID: 35907444
[TBL] [Abstract][Full Text] [Related]
29. Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Clinical recommendations.
Jóźwiak S; Nabbout R; Curatolo P;
Eur J Paediatr Neurol; 2013 Jul; 17(4):348-52. PubMed ID: 23391693
[TBL] [Abstract][Full Text] [Related]
30. Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma.
Krueger DA; Care MM; Agricola K; Tudor C; Mays M; Franz DN
Neurology; 2013 Feb; 80(6):574-80. PubMed ID: 23325902
[TBL] [Abstract][Full Text] [Related]
31. Natural History and Current Treatment Options for Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex.
Jóźwiak S; Mandera M; Młynarski W
Semin Pediatr Neurol; 2015 Dec; 22(4):274-81. PubMed ID: 26706014
[TBL] [Abstract][Full Text] [Related]
32. Everolimus Alleviates Obstructive Hydrocephalus due to Subependymal Giant Cell Astrocytomas.
Moavero R; Carai A; Mastronuzzi A; Marciano S; Graziola F; Vigevano F; Curatolo P
Pediatr Neurol; 2017 Mar; 68():59-63. PubMed ID: 28162859
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study.
Saffari A; Brösse I; Wiemer-Kruel A; Wilken B; Kreuzaler P; Hahn A; Bernhard MK; van Tilburg CM; Hoffmann GF; Gorenflo M; Hethey S; Kaiser O; Kölker S; Wagner R; Witt O; Merkenschlager A; Möckel A; Roser T; Schlump JU; Serfling A; Spiegler J; Milde T; Ziegler A; Syrbe S
Orphanet J Rare Dis; 2019 May; 14(1):96. PubMed ID: 31053163
[TBL] [Abstract][Full Text] [Related]
34. Everolimus compliance and persistence among tuberous sclerosis complex patients with renal angiomyolipoma or subependymal giant cell astrocytoma.
Song X; Said Q; Tran O; Krueger DA; Bissler J
Curr Med Res Opin; 2019 Jun; 35(6):1103-1110. PubMed ID: 30550347
[TBL] [Abstract][Full Text] [Related]
35. Everolimus and giant-cell astrocytomas in tuberous sclerosis.
Jia J; Xiong L; Chen S
N Engl J Med; 2011 Feb; 364(6):577. PubMed ID: 21306252
[No Abstract] [Full Text] [Related]
36. mTOR inhibitors in the treatment of subependymal giant-cell astrocytomas associated with tuberous sclerosis.
Komotar RJ; Starke RM; Connolly ES; Sisti MB
Neurosurgery; 2011 Apr; 68(4):N24-5. PubMed ID: 21792104
[No Abstract] [Full Text] [Related]
37. Pathological Findings of a Subependymal Giant Cell Astrocytoma Following Treatment With Rapamycin.
Cheng S; Hawkins C; Taylor MD; Bartels U
Pediatr Neurol; 2015 Sep; 53(3):238-242.e1. PubMed ID: 26173783
[TBL] [Abstract][Full Text] [Related]
38. Possible prevention of tuberous sclerosis complex lesions.
Kotulska K; Borkowska J; Jozwiak S
Pediatrics; 2013 Jul; 132(1):e239-42. PubMed ID: 23733802
[TBL] [Abstract][Full Text] [Related]
39. Maintenance therapy with everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis (the EMINENTS study).
Trelinska J; Dachowska I; Baranska D; Stawiski K; Kotulska K; Fendler W; Jozwiak S; Mlynarski W
Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 27860334
[TBL] [Abstract][Full Text] [Related]
40. Acute Management of Symptomatic Subependymal Giant Cell Astrocytoma With Everolimus.
Arroyo MS; Krueger DA; Broomall E; Stevenson CB; Franz DN
Pediatr Neurol; 2017 Jul; 72():81-85. PubMed ID: 28511812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]